Blood Plasma Study

Statistically significant effects of hyperbolic field exposure on blood plasma coagulation, confirmed across 7 patients with p = 0.027.

Learn More

Who We Are?

ASRP LLP, based in Baikonur, Kazakhstan, is a research organization specializing in hyperbolic field technologies and their biological applications. This study was conducted in collaboration with Olesya Chirkova of SASU Point Rouge (France), with a core team of Denis Banchenko (CEO), Valeria Ovsyannikova (CBO), and Mykhailo Kapustin (CTO).

Our Mission

Our mission is to understand whether non-chemical field effects can meaningfully influence fundamental biological processes such as blood coagulation. By demonstrating reproducible, statistically significant modulation of clotting dynamics, we aim to advance a new class of non-pharmaceutical coagulation control. The study is preregistered on OSF (osf.io/8q42f, DOI: 10.17605/OSF.IO/GWA9E), ensuring full transparency.

Project Goal

The goal is to establish reproducible, peer-reviewable evidence that hyperbolic field exposure can modulate blood coagulation in a channel-specific manner. Success means achieving statistical significance (target p < 0.05) across multiple patients and building a foundation for future clinical applications in non-pharmaceutical coagulation control.

Key Findings

Channel 19 — Accelerated Lifecycle:

Description:

Channel 19 produced 37% fewer clots and 42% smaller clot area compared to control samples. It was the only channel to trigger lysis — the dissolution of clots — causing samples to behave as though they had aged. This accelerated coagulation lifecycle points to a mechanism that could fast-track natural clot resolution without pharmaceutical intervention.

Channel 21 — Delayed Coagulation:

Description:

Channel 21 reduced clot formation to 41% versus 65% in untreated controls, while producing notably dense clot structures. Samples appeared biologically younger, suggesting a delayed onset of the coagulation cascade. This channel demonstrates the potential to slow clotting processes through non-chemical, field-based methods.

Applications & Intellectual Property:

Description:

The ability to accelerate or delay coagulation without drugs opens significant commercial opportunities in wound management, blood storage optimization, surgical preparation, and novel anticoagulation therapies. The underlying technology is protected by patent KZ 2025/1095.1 (Fractal Biomedical System), filed in Kazakhstan, providing a defensible IP position for future commercialization.